CYDXCYduct Diagnostics, Inc.
The schedule
- Thu15Oct
Due to ongoing negative free cash flow and depleted reserves, the company will likely be forced to execute a highly dilutive equity offering or issue convertible debt to maintain operations.
- Wed10Feb
Expected early-year update on diagnostic product uptake, potentially highlighting new enterprise accounts or an improved regulatory pathway under President Trump's FDA administration.
- Thu25Feb
Q3 2026 earnings will reveal if the 38% YoY revenue growth seen early in the year is sustainable or if operations have contracted due to undercapitalization.
- Thu27May
Q4 results will finalize the 2026 fiscal year performance and deliver critical 2027 revenue guidance.
- Thu26Aug
Past
- Thu27Aug
CYduct Diagnostics is expected to release its Q2 2026 earnings, which will heavily focus on cash runway, with only $8,976 in cash reported at the end of Q1 against a $709k debt load.